NEYPPC Pharmacy - Unlicensed Imported Medicines (wave 2)
The contract covers a framework agreement for supplying unlicensed imported medicines to NHS organisations and other eligible public sector bodies through the North East and Yorkshire NHS Pharmaceutical Purchasing Consortium, on behalf of Leeds Teaching Hospitals NHS Trust. The medicines will include defined products that may require over-labelling and translation, for patients whose clinical needs cannot be met by a suitable UK-licensed alternative. Suppliers will be expected to import, distribute and supply safe, quality-assured medicines, support continuity of supply, and meet the framework’s quality, risk and commercial assessment requirements. The contract value, duration and delivery regions are not specified in the available information, although delivery is intended for participating NHS and eligible public-sector organisations. The most critical requirement is that suppliers hold all relevant MHRA licences, authorisations and approvals and demonstrate compliance with applicable Good Manufacturing Practice and Good Distribution Practice standards.
Buyer: Leeds Teaching Hospitals NHS Trust. Source: Find a Tender. Updated 13 Oct 2026.
Key facts
- Estimated value: £36.1m
- Bids close: 30 Nov 2026
- Location: Leeds
- Procedure: Competitive flexible procedure
- Contract period: 1 May 2027 to 31 Dec 2028
- Category: Pharmaceutical products (33600000)
From the official notice
The North East and Yorkshire NHS Pharmaceutical Purchasing Consortium intends to establish a framework agreement for the supply of Unlicensed Imported Medicines on behalf of NHS organisations and other eligible public sector bodies. The framework will provide access to a defined range of unlicensed imported medicines, including products requiring over-labelling and translation. These medicines do not hold a UK Marketing Authorisation but are licensed in their country of origin and may be imported and supplied in accordance with Regulation 167 of the Human Medicines Regulations 2012 where a patient's clinical needs cannot be met by a suitable licensed alternative. Suppliers will be required to hold all relevant MHRA licences, authorisations and approvals necessary to import, distribute and supply unlicensed medicines within the UK, and to demonstrate compliance with applicable Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) standards. The framework will provide participating organisations with access to safe, compliant and quality-assured products through a robust and competitive procurement arrangement. Products and suppliers will be subject to comprehensive quality, risk and commercial assessment to support regulatory compliance, supply chain resilience, continuity of patient care and value for money across the NHS.
View the official notice
Questions about this tender
When is the deadline?
Bids close on 30 Nov 2026.
What is it worth?
The estimated value is £36.1m.
Who can apply?
The buyer has marked it as suitable for small and medium-sized businesses.
How do I bid?
Open the official notice, register on the buyer's portal and submit your bid before the deadline.
Similar tenders
Contains public sector information licensed under the Open Government Licence v3.0.
See all live tenders